The stock of Genenta Science SpA ADR (GNTA) has gone down by -4.06% for the week, with a -7.13% drop in the past month and a -26.32% drop in the past quarter. The volatility ratio for the week is 6.00%, and the volatility levels for the past 30 days are 8.73% for GNTA. The simple moving average for the last 20 days is -2.47% for GNTA stock, with a simple moving average of -11.21% for the last 200 days.
Is It Worth Investing in Genenta Science SpA ADR (NASDAQ: GNTA) Right Now?
The stock has a 36-month beta value of 0.68. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
On March 19, 2025, the average trading volume of GNTA was 11.14K shares.
GNTA) stock’s latest price update
Genenta Science SpA ADR (NASDAQ: GNTA) has seen a decline in its stock price by -0.53 in relation to its previous close of 3.80. However, the company has experienced a -4.06% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-19 that MILAN and NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) — Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 million ($21.9 million) financing through the issuance of a Mandatory Convertible Bond to ENEA Tech and Biomedical (ETB) to support the expansion of its pipeline by advancing Temferon in metastatic Renal Cell Cancer (mRCC). ETB is a leading private foundation, supervised by the Italian Ministry of Enterprises and Made in Italy, managing over €1,7 billion in assets under management through two funds.
Analysts’ Opinion of GNTA
Many brokerage firms have already submitted their reports for GNTA stocks, with ROTH MKM repeating the rating for GNTA by listing it as a “Buy.” The predicted price for GNTA in the upcoming period, according to ROTH MKM is $15 based on the research report published on June 29, 2023 of the previous year 2023.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see GNTA reach a price target of $25. The rating they have provided for GNTA stocks is “Buy” according to the report published on July 25th, 2022.
Maxim Group gave a rating of “Buy” to GNTA, setting the target price at $21 in the report published on January 13th of the previous year.
GNTA Trading at -5.64% from the 50-Day Moving Average
After a stumble in the market that brought GNTA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.08% of loss for the given period.
Volatility was left at 8.73%, however, over the last 30 days, the volatility rate increased by 6.00%. Over the last 50 days, in opposition, the stock is trading -12.44% lower at present.
During the last 5 trading sessions, GNTA fell by -3.55%, which changed the moving average for the period of 200-days by +17.65% in comparison to the 20-day moving average, which settled at $3.88. In addition, Genenta Science SpA ADR saw -13.10% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for GNTA
The total capital return value is set at -0.56. Equity return is now at value -42.81, with -38.96 for asset returns.
Based on Genenta Science SpA ADR (GNTA), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -0.27.
Currently, EBITDA for the company is -11.69 million with net debt to EBITDA at 0.66. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.30.
Conclusion
To sum up, Genenta Science SpA ADR (GNTA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
